NCT06774131Phase 3Recruiting

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Study sponsor: UroGen Pharma Ltd. · URGN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-03Estimated
Enrollment · participants70Estimated
Source updated2026-09-03Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Oct 2026. After: Mar 2027.

Check registry source

· 2 fields changed

Planned enrollment increased by 20 participants

Before: 50 participants (planned). After: 70 participants (planned).

Primary completion date changed

Before: 31 Mar 2026. After: Oct 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview